Csenge Advisory Group’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Csenge Advisory Group’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$233K	Buy	+2,856	New	+$237K	0.01%	660

Other funds holding BIB

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CIA

Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return

KFS

Kaizen Financial Strategies Campbell, California $236M AUM 28.3% 1-Year Est. Return

PWM

Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

ATPW

Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return

Csenge Advisory Group's BIB Position: Q1 2026 in Review

Csenge Advisory Group opened a new position in ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2026: 2,856 shares worth $233K. The stake represents 0.01% of the portfolio and ranks #660 among its holdings.

23 funds tracked by Wall St. Rank hold BIB as of Q1 2026.

Csenge Advisory Group held 2,856 shares of ProShares Ultra NASDAQ Biotechnology worth $233K as of Q1 2026.
ProShares Ultra NASDAQ Biotechnology was a new Csenge Advisory Group position in Q1 2026.
ProShares Ultra NASDAQ Biotechnology made up 0.01% of Csenge Advisory Group's portfolio in Q1 2026, its #660 holding.
23 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2026.

Based on Csenge Advisory Group's 13F filing for Q1 2026, filed 30 Apr 2026.